{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024727","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.679640+00:00","generated_at":"2026-06-21T20:35:33.125932+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Prelude Q3 net loss $30.0M; FDA clears two INDs, halts PRMT5 internal development","bullets":["Net loss of $30.0M ($0.63 per share) vs $30.7M ($0.66) in Q3 2021.","Cash, equivalents & marketable securities $224.0M; runway into Q4 2024.","FDA cleared INDs for PRT3789 (SMARCA2 degrader) and PRT3645 (brain-penetrant CDK4/6 inhibitor).","Discontinues internal PRMT5 program (PRT543, PRT811) to focus on higher-potential assets.","PRT2527 CDK9 Phase 1 dose escalation on track for RP2D by year-end; no dose reduction AEs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024727","json":"https://secwatch.observer/filing/0000950170-22-024727.json","markdown":"https://secwatch.observer/filing/0000950170-22-024727.md","text":"https://secwatch.observer/filing/0000950170-22-024727.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017022024727/0000950170-22-024727-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017022024727/prld-20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:35:33.125932+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a51c7d38e9a52f8c5b3d08b56e74b896d1aee79","claim":"Prelude Therapeutics Inc reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 14, 2022, Prelude Therapeutics Incorporated (the \"Company\") issued a press release announcing its financial results for the three months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017022024727/0000950170-22-024727-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}